Dice Therapeutics is a biotechnology company committed to discovering and developing novel treatments to address various unmet medical needs. The firm’s unique approach leverages a proprietary platform, which enables targeted protein degradation (TPD) using small molecules. This technology is designed to eliminate disease-causing proteins from cells, potentially offering a more effective therapeutic approach for a wide range of conditions.
The company’s pipeline includes a number of preclinical programmes targeting different diseases. Dice Therapeutics is particularly focusing on oncology and immunology, aiming to provide innovative solutions for patients who currently lack satisfactory treatment options. The firm’s team comprises industry veterans with extensive experience in drug discovery and development, underpinning its commitment to advancing novel treatments to the market.
Dice Therapeutics is also committed to partnering with other organisations to maximise the potential of its platform. The company believes that such collaborations can accelerate the development of novel therapies, furthering its mission to improve patient outcomes. It is headquartered in San Francisco Bay Area, with a presence in Boston, demonstrating its broad footprint in the biotechnology space.
Go to source article: https://www.dicetherapeutics.com/